Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
Keith Markey has been an equities analyst for more than 25 years, specializing in the biotechnology, pharmaceutical, medical device and research tools sectors. He is currently the science director for Griffin Securities Inc., an investment bank where he follows emerging healthcare companies with novel technologies. He also works with privately owned companies, helping them restructure their operations, license products under development or near commercialization and raise funds from venture capital and high net-worth investors. In addition, Markey serves on the board of directors of DS Healthcare Group, which specializes in products that address hair loss. Previously, he held various managerial positions in the Research Department of Value Line Inc., publisher of the Value Line Investment Survey and Value Line Select. Markey began his career as a biochemist, working in the fields of endocrinology and neuroscience at New York University Medical School and Weill Cornell Medical College. His research, which involved several international collaborations and resulted in more than 30 scientific publications, contributed to the understanding of regulatory biochemistry of the nervous system and stem cell plasticity. Markey received his doctorate in neurochemistry from the University of Connecticut and a master's degree in business administration and finance from the Leonard N. Stern School of Business at New York University.
Don't Miss the Boat on Big Biotech Catalysts: Keith Markey (4/10/14) Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects, and one medical device and supply company with serious growth potential. Be warnedŚhuge catalysts are on the horizon that investors won't want to miss.
Griffin Securities' Keith Markey Gives Performance Reviews on Four Favorite Biotech Names (9/12/13) As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss.
7 Big Growth Stories in Biotech: Keith Markey (3/28/13) As a former biotechnology researcher and 25-year Wall Street veteran, Griffin Securities Inc. Analyst and Scientific Director Keith Markey understands how novel, cutting-edge technology can produce extraordinary new products that bring in revenues with double-digit growth potential. Markey reveals his best ideas in this Life Sciences Report interview, providing his growth thesis for every name and describing why each has potential for at least a double.
"SYN's Trimesta has the potential to make a meaningful contribution clinically and bring sizable financial rewards to the company." (6/26/13) Synthetic Biologics Inc. - Keith Markey, Griffin Securities Moreá>
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey Moreá>
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan Moreá>